{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:49:49Z","timestamp":1789181389186,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with transplant\u2010ineligible (TIE) newly diagnosed multiple myeloma (NDMM). As there are no randomized head\u2010to\u2010head studies of DRd versus VRd, this analysis aimed to compare real\u2010world time\u2010to\u2010next\u2010treatment (TTNT) or death in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with NDMM who received front\u2010line (FL) DRd or VRd were identified from the Acentrus database (January 1, 2018 to May 31, 2023). Those with a record of a stem cell transplant or aged &lt;\u200965\u2009years were excluded to limit analysis to the TIE population. Inverse probability of treatment weighting was used to balance baseline patient characteristics. A doubly robust Cox proportional hazards model was used to compare TTNT or death between cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 149 and 494 patients who initiated DRd and VRd, respectively, were identified. After weighting (weighted N\n                      <jats:sub>DRd<\/jats:sub>\n                      \u2009=\u2009302, weighted N\n                      <jats:sub>VRd<\/jats:sub>\n                      \u2009=\u2009341), cohorts had similar baseline characteristics. Of these, 98 (32.4%) DRd and 175 (51.2%) VRd patients either received a subsequent line of therapy or died, with a median TTNT or death of 37.8\u2009months in the DRd cohort and 18.7\u2009months in the VRd cohort (hazard ratio: 0.58, 95% confidence interval: 0.35, 0.81;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of TIE NDMM patients with DRd led to a significantly longer TTNT or death compared to VRd, evidenced by a 42% risk reduction, supporting the effectiveness of DRd over VRd as FL treatment in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.70308","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T18:47:12Z","timestamp":1730486832000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Time to Next Treatment or Death Between Front\u2010Line Daratumumab, Lenalidomide, and Dexamethasone (\n                    <scp>DRd<\/scp>\n                    ) Versus Bortezomib, Lenalidomide, and Dexamethasone (\n                    <scp>VRd<\/scp>\n                    ) Among Transplant\u2010Ineligible Patients With Multiple Myeloma"],"prefix":"10.1002","volume":"13","author":[{"given":"Doris\u00a0K.","family":"Hansen","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center &amp; Research Institute  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gautam","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6927","authenticated-orcid":false,"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Moore","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabelle","family":"Tardif\u2010Samson","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Thompson\u2010Leduc","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex\u00a0Z.","family":"Fu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3863"},{"key":"e_1_2_12_3_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results (SEER) \u201cCancer Stat Facts: Myeloma \u201dhttps:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1827253"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2698"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02096"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000404"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00135\u20105"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.06.014"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_12_13_1","unstructured":"NCCN \u201cReferenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.4.2024.\u00a9 National Comprehensive Cancer Network Inc. 2024. All rights reserved \u201daccessed [May 1 2024]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(16)31594\u2010x"},{"key":"e_1_2_12_16_1","unstructured":"US Food and Drug Administration \u201cFDA Approves Daratumumab for Multiple Myeloma Ineligible for Autologous Stem Cell Transplant \u201dhttps:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010daratumumab\u2010multiple\u2010myeloma\u2010ineligible\u2010autologous\u2010stem\u2010cell\u2010transplant."},{"key":"e_1_2_12_17_1","unstructured":"SWOG Cancer Research Network \u201cComparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment \u201d(NCT05561387) https:\/\/clinicaltrials.gov\/study\/NCT05561387."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.09.003"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8037"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25963"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010019\u20100205\u20109"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1683736"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.05.013"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002083\u20108"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.009"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u20100311\u20108"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00466\u20106"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003050\u20102"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001488\u20108"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010163335"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(23)00217\u2010x"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:55:41Z","timestamp":1765284941000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":35,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/cam4.70308"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70308","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70308"}}